Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

See all formats and pricing


Select Volume and Issue


30,00 € / $42.00 / £23.00

Get Access to Full Text

Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?

Gian Paolo Rossi
  • 1Department of Clinical and Experimental Medicine (DMCS-Internal Medicine 4), School of Medicine, University of Padua, Padua, Italy
/ Teresa Maria Seccia
  • 2Department of Clinical and Experimental Medicine (DMCS-Internal Medicine 4), School of Medicine, University of Padua, Padua, Italy
/ Achille Cesare Pessina
  • 3Department of Clinical and Experimental Medicine (DMCS-Internal Medicine 4), School of Medicine, University of Padua, Padua, Italy
Published Online: 2007-12-08 | DOI: https://doi.org/10.1515/CCLM.2007.353


Experimental and observational studies support a role of plasma homocysteine levels (tHcy) in coronary artery disease (CAD). In the GENICA (Genetic and Environmental factors In Coronary Atherosclerosis) study, we found that high tHcy predicted cardiovascular mortality in hypertensive, but not in normotensive, patients independently of CAD and history of myocardial infarction. Moreover, despite not being associated with the coronary atherosclerotic burden, tHcy was inversely associated with left ventricular (LV) ejection fraction. This inverse relationship between LV systolic function and tHcy, which has been independently confirmed, might explain the association of tHcy with the risk of incident heart failure documented in the Framingham Heart Study. Thus, additional mechanistic investigation taking into consideration the effects of tHcy on LV function is necessary to further explore the potential therapeutic usefulness of tHcy lowering treatment in CAD.

Clin Chem Lab Med 2007;45:1645–51.

Keywords: cardiac dysfunction; coronary artery disease; homocysteine

Corresponding author: Prof. Gian Paolo Rossi, MD, FACC, FAHA, DMCS-Clinica Medica 4, University Hospital, Via Giustiniani, 2, 35126 Padova, Italy Phone: +39-049-821-3304/2279, Fax: +39-049-880-2252,

Received: 2007-08-16

Accepted: 2007-09-25

Published Online: 2007-12-08

Published in Print: 2007-12-01

Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 12, Pages 1645–1651, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: https://doi.org/10.1515/CCLM.2007.353, December 2007

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

D. Rosenberger, R. Gargoum, N. Tyagi, N. Metreveli, U. Sen, C. Maldonado, and S. Tyagi
Nutrition, Metabolism and Cardiovascular Diseases, 2011, Volume 21, Number 7, Page 492

Comments (0)

Please log in or register to comment.